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As the most common cause of death and disability, globally, heart disease remains
an incompletely understood enigma. A growing number of cardiac diseases are being
characterized by the presence of misfolded proteins underlying their pathophysiology,
including cardiac amyloidosis and dilated cardiomyopathy (DCM). At least nine precursor
proteins have been implicated in the development of cardiac amyloidosis, most commonly
caused by multiple myeloma light chain disease and disease-causing mutant or wildtype
transthyretin (TTR). Similarly, aggregates with PSEN1 and COFILIN-2 have been identified
in up to one-third of idiopathic DCM cases studied, indicating the potential predominance
of misfolded proteins in heart failure. In this review, we present recent evidence linking
misfolded proteins mechanistically with heart failure and present multiple lines of new
therapeutic approaches that target the prevention of misfolded proteins in cardiac TTR
amyloid disease. These include multiple small molecule pharmacological chaperones
now in clinical trials designed specifically to support TTR folding by rational design,
such as tafamidis, and chaperones previously developed for other purposes, such as
doxycycline and tauroursodeoxycholic acid. Last, we present newly discovered non-
pathological “functional” amyloid structures, such as the inflammasome and necrosome
signaling complexes, which can be activated directly by amyloid. These may represent
future targets to successfully attenuate amyloid-induced proteotoxicity in heart failure,
as the inflammasome, for example, is being therapeutically inhibited experimentally
in autoimmune disease. Together, these studies demonstrate multiple novel points in
which new therapies may be used to primarily prevent misfolded proteins or to inhibit
their downstream amyloid-mediated effectors, such as the inflammasome, to prevent
proteotoxicity in heart failure.
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Introduction
As the most common cause of death and disability globally, heart disease remains an incompletely
understood enigma. Despite vast improvements in our understanding of the neurohormonal basis
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of heart failure, current therapies targeting this system have
reached a plateau for which new therapeutic paradigms might be
considered. A great deal of insight has recently been achieved by
our understanding of the role of protein homeostasis in the heart.
The role of misfolded proteins, once reserved as the pivotal patho-
physiological mechanism in neurodegenerative diseases, such as
Alzheimer’s disease, Huntington’s disease, and Parkinson’s dis-
ease, has now been demonstrated to be present in many types of
heart failure.
Misfolded Proteins in Cardiac Disease
A growing number of cardiac diseases are characterized by
misfolded proteins underlying their pathophysiology, including
cardiac amyloidosis and dilated cardiomyopathy (DCM). Car-
diac amyloidosis represents a broad disease entity character-
ized by misfolded proteins forming insoluble aggregates that are
deposited in the heart. While the physical morphology is shared
by all amyloid fibrils, the spectrum of affected organs and clinical
presentation and prognosis varies greatly. The prognosis is often
dependent upon the makeup of the amyloid precursor protein
and its associated pathophysiology throughout the body. At least
nine precursor proteins have been implicated in the development
of cardiac amyloidosis (1). The most common cause of cardiac
amyloidosis ismultiplemyeloma (MM), specificallyMM-secreted
monoclonal Ig light chain disease (1), followed by disease-causing
mutant or wildtype transthyretin (TTR) protein (2). Functionally,
infiltrative amyloid deposition causes a restrictive cardiomyopa-
thy (diastolic dysfunction) and subsequent systolic heart failure.
The pathophysiology of amyloid light-chain amyloidosis (AL)
(Ig light chain) cardiomyopathy was hypothesized to be due to the
extracellular deposition of fibrils, resulting in increased passive
stiffness and loss of cardiac parenchyma due to cell death (1). The
physiological impairment in diastolic filling in amyloid cardiomy-
opathy patients supported this idea (3, 4). However, evidence for
precursor toxicity has gained traction with recent correlations of
AL cardiomyopathy with ATTR cardiomyopathy function with
similar degrees of fibril deposition (5). Surprisingly, patients with
equal fibril deposition due to AL cardiomyopathy are functionally
worse than ATTR patients indicating that the infiltration itself is
not completely responsible for the dysfunction (5). Soluble factors
found circulating in AL patients may be an additional contributor
to the cardiac dysfunction. This has been shown in studies where
experimental infusion of amyloidogenic light chain proteins from
patients with severe cardiac involvement into healthy hearts. The
Abbreviations: AL, amyloid light-chain amyloidosis; CANTOS, Canakinumab
Anti-inflammatory Thrombosis Outcomes Study; CINCA, chronic neurologic
cutaneous and articular syndrome; COP9, constitutive photomorphogenesis
mutant 9; CRL, cullin-RING-ligase; CSN, COP9 signalosome; EGCG, (-)-
epigallocatechin-3-gallate; FAP, familial amyloidotic polyneuropathy; FCIS1, famil-
ial cold-induced inflammatory syndrome 1; HIF1α, hypoxia-inducible factor 1-
alpha; HSP, heat shock protein; IL-1β, interleukin-1beta; Mdm2, mouse dou-
ble minute 2 homolog; MWS, Muckle-Wells syndrome; Nec-1, necrostatin-1;
NLRP3/NALP3, NACHT, LRR, and PYD domains-containing protein 3; Poly-Q19,
poly-glutamine (19 repeats); Poly-Q83, poly-glutamine (83 repeats); p53, tumor
protein 53; RA, rheumatoid arthritis; RHIMs, RIP homotypic interaction motifs;
RIP1/RIP3, receptor-interacting protein 1/3; ROS, reactive oxygen species; TNFα,
tumor necrosis factor alpha; TTR, transthyretin; TUDCA, tauroursodeoxycholic
acid; XIAP, X-linked inhibitor of apoptosis protein.
infusion of amyloidogenic light chain proteins induced diastolic
dysfunction in healthy unaffected isolated mouse hearts, while
infusion of light chains from patients with myeloma and no
amyloidosis do not (6–9). The cardiac dysfunction in amyloid
cardiomyopathy therefore appears to be related to mechanisms
induced by both infiltrative insoluble factors in the heart itself and
circulating soluble factors from the systemic MM.
Recognition of protein aggregation as a cause of heart failure
is likely underestimated. Two recent studies illustrate the preva-
lence of protein aggregation as a cause of heart failure in patients
that had heart failure clinically characterized by DCM. Two new
sequence variants in the presenilin-1 (PSEN1) gene promoterwere
identified in nearly 1% (3/325) of patients of the idiopathic DCM
patients investigated (10). Interestingly, PSEN1 mutant patients
have cardiac protein aggregates present, along with reduced psen1
gene and PSEN1 protein expression (10). Mechanistically, PSEN1
co-immunoprecipitates with SERCA2a illustrating one point in
which PSEN1 may be affecting cardiac function (10). With the
PSEN1 oligomer interacting directly with the Ca2+ channel, it
is possible that changes in Ca2+ and heart failure seen in these
patients may be mechanistically linked by this interaction (10).
Similarly, tangles and plaque-like aggregates made of COFILIN-
2 have been found in other DCM cases, estimated to involve
nearly one-third of the cases (11). Initial studies investigated the
aggregate composition of aggregates extracted from human idio-
pathic DCM with Congo red positivity has been found to include
COFILIN-2 in a high percentage of patients, whichwas confirmed
in a larger cohort of samples (11). Aggregates had COFILIN-2
present, an actin-depolymerizing protein known to participate in
neurodegenerative diseases (12, 13). Understanding COFILIN-2’s
role in chronic degenerative diseases such as DCM offers a novel
therapeutic target (11).
Mutations in heat shock proteins (HSPs), a critical component
of the cellular “anti-folding” apparatus, also underlie human car-
diac disease. HSP proteins assist protein folding in routine main-
tenance of the cardiomyocyte. However, in the context of disease,
their recruitment to protein misfolding is critical with acquired
conditions such as ischemia/reperfusion injury, or because of
mutations which can modify protein structures (14). In Long
QT Syndrome 2, mutations in KCNH2 (aka human ether-a-go-
go related gene/HERG) encoding the rapidly activating-delayed
rectifier potassium channel Kv11.1 alpha-subunit alter cell repo-
larization of the ventricular action potential (15). Characterized
by prolonged QT interval and ventricular tachycardia, syncope,
and sudden death, the largest number of HERGmutations (28/34)
affect protein folding and trafficking (16). Similarly, the desmin
contractile apparatus linking nucleus, mitochondria, and sar-
colemma is critical to cardiomyocyte function. Desmin deficiency
or mutations in the chaperone proteins assisting desmin fold-
ing, e.g., HSPA/HSP70, HSPH (HSP110), DNAJ (HSP40), HSPB
(small HSPs), SHPD, HSPE, CCT, result in proteotoxicity medi-
ated via aggregate formation (14).
Protein Folding, Preamyloid Oligomers,
and Aggregation
In biological systems, multiple physical factors influence protein
folding (17), including mutations, molecular chaperones, and
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FIGURE 1 | Native, non-native, aggregates, and amyloid protein
structures, and the stressors that drive them. (A) Proteins are prone to
misfolding by direct biological and indirect environmental stresses, including
alterations in the protein sequence (mutations) and post-translational
modifications (e.g., those induced by oxidative stress), respectively, creating
protein aggregates and amyloid. These toxic structures are dangerous to
biological systems, driving amyloidosis in neurodegenerative and cardiac
pathologies. (B) Unfolded protein resides at a high entropy state in an
unstable “non-native” structure. As they become folded, they move toward a
lower entropy and move toward stable and favorable “native” structure.
(C) Biological and environmental stressors initiate alterations in protein
sequence (i.e., mutations), forcing intermediates into unstable conformations.
(D) Destabilized proteins accumulate resulting into misfolded protein
aggregates and amyloid with more stable conformations. (B–D): © Bentham
Science. Used with permission from Gomes (20).
protein quality control systems (such as the ubiquitin proteasome
system), which prevent the formation of misfit conformations
resulting from destabilized protein folding and/or aggregate for-
mation (18, 19). Protein misfolding is driven by alterations in the
protein sequence (i.e., mutations), malignant post-translational
modifications, and oxidative stress among other environmental
cues (Figure 1A). These alterations initiate pathology through:
(1) formation of a destabilized protein; (2) accumulation of inter-
mediates with unstable folding, and (3) stabilization of mis-
folded protein conformations through the formation of aggregates
(Figures 1B–D). While native conformation stability is character-
ized as having achieved the lowest free energy state, this feature
may also explain the stability of aggregate/fibril formation in dis-
eases, including heart failure in amyloidosis and non-amyloidosis-
related states.
Protein folding is a process through which polypeptide chains
wrap themselves to achieve optimal stability in their physiolog-
ical environment (Figure 1B) (21). This process results from
the lower energy “native-like” interactions that are more stable
than “non-native-like” conformations (Figure 1C) (20). As favor-
able interactions are established, proteins transition from a high
entropy state to one with a lower entropy structure. Proteins
therefore have a range of free energies they can move through,
inevitably proceeding through a set of conformations that nar-
row as the native state is achieved (22–24). Typically for small
globular proteins, this transition has been likened to that of a
funnel, where inter- and intra-domain interactions cooperatively
interact to establish a stable native confirmation (25). Adverse
conditions or mutations result in a degeneration of the energetic
minimum, resulting in the lowering of barriers between native-
like conformations (Figure 1D). The resulting larger distribution
results in higher energy amyloidogenic conformers in destabilized
folding patterns, susceptible to degradation or consequent local
unfolding that triggers aggregation. These conformers can then
contribute to the assembly into amorphous organized aggregates
into fibrils results from interactions between stabilized aggregates
(Figure 1D).
Protein Aggregates, Proteotoxicity, and
Heart Failure
Protein aggregates and their preceding intermediates induced cell
death is a process described as proteotoxicity (Figure 2). These
designations refer to a protein’s state, not its origin as many differ-
ent types of proteins can form these misfolded proteins. However,
most familiar examples of aggregates tend to be recognized for
their specific sources, such as β-amyloid (AB) and α-synuclein
found in Alzheimer’s and Parkinson’s disease, respectively. Mis-
folded protein aggregation leading to heart failure has been found
to be caused by misfolded TTR and excessive immunoglobulin
resulting from aging or mutations and MM, respectively. Solu-
ble oligomers and aggregated proteins disrupt cellular function
by interfering with proteasome function, disrupting cell signal-
ing, and protein trafficking, and directly support signals that
induce cell death (26, 27). The accumulation of misfolded protein
oligomers have been identified in patients with hypertrophic car-
diomyopathy, idiopathic DCM, and Becker’s muscular dystrophy,
but not in healthy controls (28). In DCM, cytosolic aggregates
colocalize with ubiquitin and increased autophagy has been iden-
tified (29). Autophagy, a mechanism for removing aggregated
proteins,may be oneway inwhich the heart clears the pathological
buildup of misfolded proteins.
The link between misfolded proteins, proteotoxicity, and heart
failure has just recently been made. Early correlations between
misfolded proteins and heart disease were made in mouse models
of cardiac hypertrophy, where aggregation of misfolded proteins
and aggresomes were identified (30). Further, inhibiting pro-
teasome activity resulted in the accumulation of ubiquitinated
protein aggregates and enhanced autophagy (30). However, it
was not until the toxic effects of misfolded proteins in the heart
were tested directly that the causal link of misfolded proteins
to proteotoxicity and heart failure was made. In these studies,
mouse hearts expressing small oligomers prone to misfolding
(poly-Q83) were compared to hearts expressing a similar but
non-oligomer forming peptide repeat (poly-Q19) (31). Mice with
cardiac PQ83 developed heart failure by 5months of age, whereas
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FIGURE 2 | Protein aggregate and amyloid stimulate cellular
dysfunction. Misfolded protein aggregates and amyloid inhibit normal
proteasome function, interfere with cellular signaling and trafficking, and
induce apoptotic cell signaling pathways. All of these perturbations have been
shown to occur in cardiac pathologies, such as hypertrophic cardiomyopathy,
idiopathic dilated cardiomyopathy, and Becker’s muscular dystrophy.
the non-aggregating control PQ19’s heart functionwas completely
normal (31). These studies develop a new paradigm by which to
consider how protein aggregation may contribute to heart failure
and ischemic heart disease (32, 33), as well as genetic diseases
associated with protein misfolding and cardiac dysfunction.
How Endogenous Systems Prevent Protein
Misfolding
Cells have adapted mechanisms to counteract the propensity of
a protein to misfold, particularly in the face of common cel-
lular challenges, such as oxidative stress, and the routine post-
translational modifications that can accumulate on proteins.
The ubiquitous HSPs act as molecular chaperones to counteract
the stress-induced denaturation of other proteins. In the heart, the
cardio-protective effect of HSP90, HSP70, TRiC, as well as a host
of small HSPs [αBCrystallin (aka HSPB5), HSP20 (aka HSPB6),
HSP22 (aka HSPB8, H11 kinase, and αCCrystallin), HSP27 (aka
HSPB1 and HSPB2), and HSP60], has been described in the
context of cardiac hypertrophy, heart failure, and ischemia reper-
fusion disease (34). Their ability to protect the misfolding of
specific targets, such as actin, tubulin, desmin, lipid membranes,
andmediators of cell death (e.g., Bax/Bak) have been implicated to
date, though a thorough description of their role is just beginning
to be elucidated (34).
Not only do chaperones play a role in maintaining proper
protein folding, they have overlapping functions that might be
useful when thinking about new therapeutic interventions in
targeting protein misfolding. HSPs have overlapping functions –
the integrity of a single protein can be maintained by >1 HSP
in most cases. Recent studies have provided a proof of concept
of how this knowledge may be applied therapeutically. Briefly,
cultured cardiac cells with disease causing mutations in CryAB
mediate cell death and dysfunction; as the complementary HSPB1
is introduced into the cells, both the aggregate formation and
associated toxicity are relieved (35). As a consequence of this rela-
tionship, overexpressing HSPB1 facilitates the ubiquitination and
proteasome degradation of protein aggregates induced bymultiple
CryABmisfoldingmutations (35), illustrating that increasingHSP
expression can help enhance both the solubility and degrada-
tion of misfolded proteins in cardiomyocytes. Similarly, treat-
ment of the CryABR120G mutant mouse model of desmin-related
cardiomyopathy with the drug geranylgeranyl-acetone (increas-
ing HSPB8 and HSPB1) significantly reduces heart failure (36).
CryABR120G transgenic mice treated with geranylgeranyl-acetone
have reduced amyloid oligomer formation, decreased fibrosis, and
recovery of heart function, and overall survival (36).
Pharmacological Chaperone Therapies
Establishing the role of misfolded proteins in heart failure gives
context to the emerging development of small molecule phar-
macological chaperones (37–39). Pharmacological chaperones are
defined as molecules which act specifically onmisfolded or desta-
bilized protein substrate(s) to specifically refold or stabilize these
proteins, respectively (40). Pharmacological stabilization of the
protein TTR and amyloid fibril disruptors are being developed
for polyneuropathy. More recently, their applicability to amyloid
disease in the heart has been demonstrated, and they are now
undergoing clinical trials for cardiac amyloidosis due tomisfolded
TTR.Mutations and aging causemisfolding to result in TTR amy-
loidosis, and pharmacological chaperone therapy has successfully
been used to treat both forms.
Initial studies investigating pharmacological chaperone ther-
apy focused on the neurological manifestations of TTR amy-
loidosis. Extracellular deposition of TTR is a hallmark of the
fatal autosomal dominant neurodegenerative familial amyloidotic
polyneuropathy (FAP) (41), inwhich bothmutant (familial forms)
and wild type (senile/aging forms) aggregate. More than 80 dif-
ferent mutations destabilize TTR and prevent formation of the
tetramer and promote aggregation of misfolded monomers (42).
Misfolded TTR, also known as pre-albumin, is a protein syn-
thesized by the liver that forms a soluble homotetramer, which
acts to transport thyroid hormone (T4) and retinol. Extensive
screening in aggregate-prone conditions led to the discovery of
multiple aromatic small molecules that stabilize mutant TTR
(43). These molecules, including specific NSAIDs and natu-
rally derived flavonoid and xanthones, function by binding to
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thyroxine-binding sites in TTR to stabilize its structure (43).
This led to the development of a wide range of compounds
from different structural families, including enzoxazoles (44, 45).
Tafamidis, a derivative enzoxazole, was selected for clinical devel-
opment based on its ability to stabilize mutant TTR in vitro,
and was later found to have a therapeutic effect in neurological
disease models (46, 47). While occupying the thyroxine-binding
sites, tafamidis’s negative cooperativity acts to stabilize the TTR
tetramer.
The first human study of tafamidis for the treatment of
polyneuropathy associated with TTR mutations was reported
in 2012. Patients with the V30M TTR mutation and FAP were
treatedwith 20mgdaily for 18months (47). The primary objective
was to monitor progression of neuropathy and to evaluate drug
safety, while a secondary objective was to determine if tafamidis
exhibits a stabilizing effect on human V30M TTR. A total of
128 patients were randomized to tafamidis or placebo. Significant
reduction in neuropathy impairment scores were identified as
early as 6months and continued through 18months (47). The
changes in small nerve fiber function scores were attenuated by
tafamidis, while allowing significant increases in BMI to occur
(reflecting less muscle mass loss/atrophy resulting from the dis-
ease process) (47). Oral tafamidis is now approved in the EU for
the treatment of TTR amyloidosis in adult patients with early stage
symptomatic polyneuropathy to delay neurologic impairment. In
Argentina, Japan, and Mexico, tafamidis is approved for use in
delaying peripheral neurological impairment of TTR FAP (48). In
the US, the FDA has requested a second efficacy study before it
will grant approval, while noting that the data provided internal
consistency and replication of effect.
In addition to neurodegeneration, patients with TTR-FAP
develop cardiac disease. At least five clinical trials that investigate
tafamidis in patients with TTR-related cardiomyopathy are active
or have been completed (see Table 1). The first one recently
published was a randomized crossover study in healthy volunteers
that determined tafamidis did not have any effect on QTc inter-
vals or serious adverse events in 42 subjects (49). Inhibition of
TTR expression using siRNA therapy is yet another therapeutic
approach being tested to treat TTR-related cardiomyopathy (see
Table 1, rows 6–7).
Pfizer’s tafamidis and its potential to stabilize amyloid
cardiomyopathy (TTR) are just the tip of the iceberg in
the development of pharmacological chaperones for heart
disease. Multiple other anti-amyloidogenic compounds have
been discovered, including: (1) AG10, (2) doxycycline, (3)
tauroursodeoxycholic acid (TUDCA), (4) (-)-epigallocatechin-3-
gallate (EGCG), and (5) curcumin. High throughput screening
for compounds that bind to the T4 pocket of TTR under
physiological conditions identified AG10, which has higher
affinity for TTR and greater pharmacokinetic stability while
being more selective than tafamidis and diflunisal (a salicylic
acid derivative) at physiological conditions (50). In in vitro
studies, AG10 was found to effectively inhibit the proteotoxicity
of V122I-TTR in human cardiomyocytes (50). AG10 inhibits
aggregation of both wild-type TTR (associated with aging) and
V122I-TTR significantly better than tafamidis, and almost fully
stabilizes TTR at 10 µm plasma concentrations (42). AG10 is
a bivalent molecule and thus able to bind 2 TTR proteins per
molecule, allowing it to simultaneously occupy adjacent T4 sites
in the TTR tetramer (42).
The discovery that tetracycline antibiotics have anti-
amyloidogenic activity comes from the observation that
iododoxorubicin (an anthracycline) is able to reduce amyloid
and improve end organ damage in AL (51, 52). Doxycycline
was then shown to act as a fibril disruptor in vitro, without
toxicity (53). In mouse models of AL amyloidosis, doxycycline
similarly disaggregated amyloid and improved tissue markers of
TTR deposition, without effecting pre-fibril aggregates (54). In
combination with the water-soluble bile acid TUDCA, synergistic
clearance of TTR deposits was observed (55). Used in treating
cholestasis in liver disease, TUDCA, like doxycycline, is an FDA
approved drug for other indications. A phase 2, open-label study
evaluating the efficacy, tolerability, safety, and pharmacokinetics
of doxycycline and TUDCA in TTR-related cardiomyopathy is
currently underway (Table 2).
Additionally, there are a number of naturally occurring
polyphenols that have anti-amyloidogenic properties, including
the polyphenols EGCG and curcumin. EGCG, found in green
tea, appears to bind amyloidogenic proteins and exert its pro-
tective effects by redirecting the aggregation process. Specifically,
alternate non-pathogenic oligomeric species are instead formed
which then deplete the formation of pathogenic types (56, 57).
In a phase 2 clinical trial, EGCG was effective in preventing the
progression of cardiomyopathy over 12months. Of the 14 patients
completing the study, no significant changes in cardiac mass or
wall thickness were found when treated with ~500–700mg EGCG
daily (58). However, wide variation in bioavailability following
oral EGCG intake is an issue complicating the clinical devel-
opment of this compound (58, 59), including suspected hepatic
toxicity (60). Still, at least three clinical trials evaluating EGCG
for protein misfolding diseases are ongoing, two of which are in
cardiac amyloidosis (Table 3). The other polyphenol, curcumin,
competes for T4 on TTR to stabilize TTR’s native structure (61),
inhibiting amyloid fibril formation in vitro, and disrupting pre-
formed TTR fibrils from generating small oligomers (62). In vivo
studies of transgenic TTR mice have demonstrated prevention
of cytotoxicity and decreases in TTR deposition (63). However,
there are no ongoing clinical trials evaluating curcumin for this
therapeutic indication.
Successful early studies of pharmacological chaperones in pre-
clinical and now clinical trials of amyloid-based disease have sup-
ported the concept that reversing/stabilizing protein misfolding is
possible and can attenuate and sometimes reverse the pathophys-
iology, even in the heart. The increasing number of clinical trials
(both phase 1 and 2) with cardiac indication holds promise that
we will better understand the efficacy and safety of these drugs in
patients with heart failure soon. While specific pharmacological
chaperones appear to be specific for theirmisfolded substrate (e.g.,
TTR), it will be interesting to see how applicable these chaperones
are to other substrates, and whether pharmacological chaperones
can be created for other substrate(s) found in differing causes of
heart failure. With limited options for patients with heart failure,
this class of drug offers a new way to treat an old but common
problem.
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TABLE 1 | Clinical studies investigating tafamidis and siRNA TTR in transthyretin-associated (amyloid) cardiomyopathy.
1. TTR cardiomyopathy: clinicaltrials.gov
NCT01775761
Estimated enrollment: 42
Estimated completion: 2013 (for primary
outcome measure)
A study to determine any effect of tafamidis on
electrocardiographic intervals, specifically the rate
corrected qt interval (qtc)
Endpoint: safety
Phase 1:
randomized, placebo, and positive controlled
cross-over study
Completed/no study results posted
Primary outcome measures:
QTc interval using Fridericia’s correction method
(QTcF) of tafamidis and placebo (baseline-adjusted)
at each post-dose time
Secondary outcome measures:
QTcF of moxifloxacin and placebo at historical
moxifloxacin median Tmax of 3 h
2. TTR cardiomyopathy: clinicaltrials.gov
NCT01655511
Enrollment: 9
Estimated completion: September 2012 (for
primary outcome measure)
Safety and pharmacokinetic assessment of orally
administered tafamidis in healthy volunteers
Endpoint: pharmacokinetics of tafamidis >120mg as
an oral solution
Phase 1:
randomized, double-blind, cross-over,
ascending dose-tolerance
Completed/no study results posted
Primary outcome measures:
safety and tolerability of orally administered tafamidis
in healthy volunteers
Secondary outcome measures:
Cmax, Tmax, AUC 0-24, AUC last, AUC Inf, T1/2
plasma decay, TTR blood concentration, TTR
stabilization
3. TTR-CM: clinicaltrials.gov NCT00925002
Estimated enrollment: 110
Estimated completion: 2021
Safety and efficacy evaluation of fx-1006a in patients
with v122i or wild-type transthyretin (ttr) amyloid
cardiomyopathy
Endpoint: safety/efficacy
Phase 3:
non-randomized, open-label evaluation of
Tafamidis in patients with TTR amyloidosis
Active, currently recruiting
Primary outcome measures:
long-term, open-label safety, and efficacy in ttr
amyloidosis patients (10 years)
Secondary outcome measures:
provide investigation product until market availability
to ATTR who have completed protocol
4. Cardiomyopathy: clinicaltrials.gov NCT00694161
Estimated enrollment: 35
Estimated completion: 2010 (final data
collection for primary outcome measure)
The effects of fx-1006a on transthyretin stabilization
and clinical outcome measures in patients with v122i
or wild-type ttr amyloid cardiomyopathy
Endpoint: safety/efficacy
Phase 2:
interventional, open label, of ttr stabilization,
and clinical outcomes in v122i or wildtype ttr
amyloid cardiomyopathy
Completed (has results, below)
Primary outcomes: participants with TTR V122I and
wildtype TTR achieved TTR stabilization at week 6
(97.1%, N= 35)
Secondary outcomes: those achieving TTR
stabilization continued through month 12 (87.5% with
stabilized TTR, N= 34) Completed (has results,
below)
5. Transthyretin (TTR) amyloid cardiomyopathy
tafamidis: clinicaltrials.gov NCT01994889
Estimated enrollment: 400
Estimated completion: August 2018
Tafamidis
Endpoint: safety/efficacy
Phase 3:
multi-center, international, double-blind,
placebo-controlled, randomized study to
evaluate efficacy, safety, and tolerability of oral
dosing of tafamidis meglumine in TTR-CM
Recruiting, no study results posted
Primary outcome measures:
all-cause mortality and frequency of cv-related
hospitalization
Secondary outcome measures:
6min walk test, Kansas City Cardiomyopathy
Questionnaire, CV-related mortality, frequency of
CV-related hospitalization, all-cause mortality, TTR
stabilization at 1month
6. TTR-mediated amyloidosis, ALN-TTRSC:
clinicaltrials.gov NCT01814839
Estimated enrollment: 76
Estimated completion: 2015
ALN-TTRSC (RNAi)
Endpoint: safety
Phase 1:
randomized, double-blind, placebo-controlled,
single and multi-dose, dose escalating study
Completed, no study results posted
Primary outcome measures:
adverse events, serious adverse events, study drug
discontinuation
Secondary outcome measures:
pharmacokinetics of ALN-TTRSC, effect of
ALN-TTRSC on Vitamin A, effect of AL-TTRSC on
retinol binding protein
7. TTR-mediated amyloidosis, ALN-TTRSC:
clinicaltrials.gov NCT01981837
Estimated enrollment: 25
Estimated completion: January 2015
ALN-TTRSC (RNAi)
Endpoint: safety/efficacy
Phase 2:
open-label trial to evaluate safety,
pharmacokinetics, pharmacodynamics, and
Exploratory Clinical Trial of ALLN-TTRSC
activity in TTR cardiac amyloidosis patients
Active, not recruiting, no study results posted
Primary outcome measures:
AEs, SAEs, study drug discontinuation
Secondary outcome measures:
pharmacokinetics of ALN-TTRSC, effect of
ALN-TTRSC on TTR
TTR, transthyretin.
Created from data available at: clinicaltrials.gov (accessed 2 February, 2015).
Are pharmacological chaperones the only way to think about
inhibiting proteotoxicity? It is possible that multiple points exist
to prevent the proteotoxicity from contributing to heart failure,
understanding that the formation of pre-amyloid oligomers,
aggregates, and amyloids itself are a continuum. Like the con-
cept of proteotoxicity itself, some of the answers may come from
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TABLE 2 | Clinical studies investigating doxycycline in transthyretin-associated (amyloid) cardiomyopathy.
8. Transthyretin amyloidosis, doxycycline+TUDCA:
clinicaltrials.gov NCT01171859
Estimated enrollment: 40
Estimated completion: July 2015 (final data
collection date for primary outcome measure)
Doxycycline+ TUDCA
Endpoint: safety/efficacy
Phase 2:
single center, non-randomized, open-label,
prospective study followed by 6months
withdrawal to evaluate efficacy, tolerability,
safety, pharmacokinetics of TUDCA in TTR
Amyloidosis
Active, not recruiting
Primary outcome measures:
response rate to TUDCA (based in mBMI reduction
<10%, change in neurologic impairment score-lower
limbs (NIS-LL) <2, and NT-proBNP <30% (or <300
pg/ml)
Secondary outcome measures:
treatment-emergent adverse events, doxycycline PK,
response in autonomic dysfunction, neuropathy and
visceral organ involvement, incidence of patients
discontinuing from study due to clinical or laboratory
adverse events
9. Amyloidosis; heart (manifestation); senile cardiac
amyloidosis; doxycycline+ TUDCA: clinicaltrials.gov
NCT01855360
Estimated enrollment: 40
Estimated completion: September 2015 (final
data collection date for primary outcome
measure)
Doxycycline+ TUDCA
Endpoint: safety/efficacy
Phase 1/2:
open-label study of TUDCA in
TTR-cardiomyopathy
Recruiting
Primary outcome measures:
rate of progression of TTR cardiac amyloidosis (strain
echocardiography)
Secondary outcome measures:
number of patients with adverse events to the
medications over the period of therapy (18months),
evaluate general and health related QoL in senile and
familial TTR amyloidosis subjects
10. Transthyretin amyloidosis; cardiomyopathy;
doxycycline+UDCA: clinicaltrials.gov NCT02016365
Estimated enrollment: 30
Estimated completion: June 2015 (final data
collection date for primary outcome measure)
Doxycycline+UDCA
Endpoint: safety/efficacy
Phase 2:
open-label study multi-center study of Safety
and Efficacy of TUDCA in ATTR amyloidosis
disease progression
Active, not recruiting
Primary outcome measures:
efficacy on serum NT-proBNP (12months)
Secondary outcome measures:
modified BMI, increase in septum thickness,
neurologic Kumamoto Scale, number of patients with
adverse events, blood work for potential drug-related
adverse events
TTR, Transthyretin; TUDCA,: tauroursodeoxycholic acid; UDCA, ursodeoxycholic acid.
Created from data available at: clinicaltrials.gov (accessed 2 February, 2015).
TABLE 3 | Clinical studies investigating ECGG in primary cardiac amyloidosis and Alzheimer’s disease.
11. Light chain (AL) amyloidosis, cardiac involvement:
clinicaltrials.gov NCT02015312
Estimated enrollment: 38
Estimated completion: September 2017 (final
data collection date for primary outcome
measure)
Green tea compound EGCG
Safety/efficacy
Phase 2:
randomized, double-blind study of
safety/efficacy
Recruiting
Primary outcome measures:
12months change in LV mass
Secondary outcome measures:
change in QoL, number of adverse events according
to CTC criteria, change in cardiac biomarkers,
hematological improvement, organ response
(non-heart), overall survival
12. Alzheimer’s disease: clinicaltrials.gov
NCT00951834
Estimated enrollment: 50
Estimated completion: June 2015 (final data
collection date for primary outcome measure)
Green tea compound epigallocatechin-3-gallete
Efficacy study
Phase 2/3:
randomized, double-blind study of efficacy
Recruiting
Primary outcome measures:
ADAS-COG (score 0–70)
Secondary outcome measures:
safety and tolerability, MMSE score after 18months
vs. baseline, time to hospitalization and time to death
related to AD, brain atrophy via MRI, baseline
ADAS-COG and baseline-MMSE as covariates,
CIBIC+ and WHO QoL Bref, trail making test, and
MVGT
13. Primary (cardiac) amyloidosis of light chain type:
clinicaltrials.gov NCT01511263
Estimated enrollment: 86
Estimated completion: December 2015 (final
data collection date for primary outcome
measure)
Green tea compound epigallocatechin-3-gallete
Efficacy
Phase 2:
open-label, randomized study of dietary EGCG
Recruiting
Primary outcome measures:
cardiac response (rate of cardiac response following
chemotherapy in patients with AL amyloidosis);
endpoint at 6months
Secondary outcome measures:
rate of adverse events, cardiac progression, time to
cardiac progression, rate of cardiac events, time to
cardiac events, survival at 6months
EGCG, epigallocatechin-3-gallete.
Created from data available at: clinicaltrials.gov (accessed 2 February, 2015).
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FIGURE 3 | The NLRP3 inflammasome is an amyloid-like fibrillar
cytokine-processing platform, which senses amyloid and contributes to
worsening heart failure. (A) Amyloid fibrils from diverse sources including
amyloid-beta, islet amyloid polypeptide, serum amyloid A, prions, and possibly
others, accumulate within cells and tissues. (B) The NLRP3 inflammasome can
activate in response to these amyloid fibrils, leading to formation of a functional
amyloid nucleated by NLRP3 and containing long polymeric repeats of ASC, the
adaptor protein, and pro-Caspase 1. The NLRP3 inflammasome is capable of
inducing a pro-inflammatory necrotic cell death, termed pyroptosis. Additionally,
the proximity of pro-Caspase 1 proteins to one another leads to their proteolytic
activation and release of active Caspase 1. Active Caspase 1 then processes
pro-IL-1β and pro-IL-18, among other proteins, leading to the secretion of the
active form of these pro-inflammatory mediators. (C) Both IL-1β and IL-18 have
been shown to directly cause cardiac dysfunction and may be targets for
pharmacologic intervention as in the CANTOS trial. (D) IL-1β and IL-18 also can
contribute to systemic inflammatory diseases characterized by massive
production of acute phase reactants such as serum amyloid A. Serum amyloid
A can then act as a seed for additional amyloid formation, which is sometimes
seen in chronic inflammatory diseases such as Muckle-Wells syndrome (MWS)
or rheumatoid arthritis (RA). In many resting cells, which do not express
components of the NLRP3 inflammasome, these components can be
upregulated through Toll-like receptor-NF-κB mediated signaling. Upon
upregulation of inflammasome components, these cells are “primed” for
inflammasome activation. It still remains to be seen whether inflammasome
activation originating in the heart or from phagocytes drives the pathogenesis of
heart failure. Additionally, studies have yet to tease out the role of NLRP3
inflammasome-mediated pyroptosis in cardiac dysfunction. (E) The
inflammatory IL-1β and IL-18 may contribute to the formation of amyloid in
neighboring cells, through unclear mechanisms. IL-18 co-localizes with
Aβ-plaques and increases the hyperphosphorylation of tau-protein (72). IL-18
enhanced cleavage of serum amyloid-β precursor protein experimentally, and
may be one mechanism of many remaining to be discovered.
emerging discoveries in neurodegenerative diseases caused by
endogenous misfolded proteins (e.g., Tau protein in Alzheimer’s
disease) or exogenous proteins (e.g., caused by prions). Next, we
introduce how the concept of altered proteostasis activates large
signaling complexes, including the inflammasome and necro-
some, as well as complexes to prevent misfolded protein-induced
cell death (proteotoxicity), such as the signalosome.
Amyloid Proteins, Heart Failure, and
Activation of the Inflammasome
The inflammasome is a large oligomeric signaling structure that
generates a robust pro-inflammatory response through coor-
dinated necrotic cell death and secretion of IL-1β and IL-18.
While the composition varies based on the activating signal, the
inflammasome generally is made up of three proteins, includ-
ing a cytosolic sensory receptor, an adaptor protein ASC, and a
Caspase 1 enzyme (64). The best characterized inflammasome,
the NLRP3 inflammasome (Figure 3), is activated by a diverse
array of infectious and sterile stimuli, which initiate signaling
through perturbation of cellular homeostasis – either through
mitochondrial disruption, ER stress, calcium influx, potassium
efflux, or some combination of these mechanisms (65, 66). When
activated, these proteins come together to form an enormous
fibrillar structure that acts as a platform for cytokine process-
ing (67–69). For example, NLRP3 mutations resulting in acti-
vation cause familial cold-induced inflammatory syndrome 1
(FCIS1),Muckle-Wells syndrome (MWS), and chronic neurologic
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cutaneous and articular syndrome (CINCA), all of which are
characterized by hyperactiveNLRP3 inflammasome signaling and
chronic inflammation. Disruption of IL-1 signaling, with either
the IL-1-receptor antagonist, Anakinra, or an anti-IL-1β mon-
oclonal antibody, Canakinumab, provides rapid and dramatic
resolution of symptoms (70, 71).
Some patients with activating mutations of NLRP3 develop
multi-organ serum amyloid A protein (AA)-type amyloidosis –
likely the result of persistently elevated levels of this acute phase
protein in response to chronic inflammation (73). AA amyloidosis
can involve deposits in the heart that lead to ventricular hypertro-
phy, atrial dilatation, and cardiac dysfunction (74–77). Although
typically thought of as rare, a recent survey of re-examined autopsy
tissues from 369 rheumatoid arthritis patients found that 30% had
evidence of AA amyloid deposits with cardiac amyloid and renal
amyloid appearing with equal frequency (78). In two recent case
reports of AA amyloidosis, treatment with anti-cytokine therapies
reduced chronic inflammation and serum amyloid A levels result-
ing in stabilized or improved cardiac manifestations of the disease
(79, 80), providing further support for the hypothesis that limiting
the availability of aggregation-prone proteins can limit amyloid
formation.
While chronic inflammation can lead to amyloidosis, studies
have also shown that the NLRP3 inflammasome can be activated
in response to different types of amyloid, including amyloid-beta,
islet amyloid polypeptide, serum amyloid A, prions, and curli
fibers, a type of amyloid found in the biofilmofEscherichia coli and
Salmonella enterica serovar Typhimurium (81–86). This diverse
collection of amyloid that triggers theNLRP3 inflammasome raise
the possibility that NLRP3 is central in generating an inflamma-
tory response to all amyloids.
We are just beginning to appreciate the role of the NLRP3
inflammasome in cardiac disease. In mice, cardiac-specific over-
expression of a constitutively active form of the calcineurin A cat-
alytic subunit leads to impaired cardiac function (87) andmyocar-
dial inflammation characterized by activation of Caspase 1 (88).
In this model, additional deletion of NLRP3 or pharmacologic
inhibition of IL-1β signaling using the IL-1-receptor antagonist
significantly reduced left ventricular dilatation and abrogated the
progressive decrease in fractional shortening (FS) observed in
wildtype and saline treated mice, thus implicating the NLRP3
inflammasome in this cardiac dysfunction (88).
In patients with idiopathic DCM, increased mRNA levels of
NLRP3 inflammasome components were associated with wors-
ening left ventricular ejection fraction, and NLRP3 and IL-1β
mRNA at the time of admission were independent predictors of
6months re-hospitalization (89). In support of a role for IL-1β
signaling in cardiac dysfunction, human atrial trabecule tissue
in an organ bath exhibited compromised systolic and diastolic
function when exposed to TNF-α and IL-1β individually, and had
additive effects when combined at low doses (90). Additionally,
in patients with rheumatoid arthritis without concurrent cardio-
vascular disease, treatment with anakinra improved non-invasive
measures of vascular and left ventricular function (91).
In 2011, a large multicenter trial called Canakinumab Anti-
inflammatory Thrombosis Outcomes Study (CANTOS), which
planned to enroll 17,200 post myocardial infarction patients,
was initiated to determine whether IL-1β inhibition can prevent
recurrent myocardial infarction, stroke, and cardiovascular death
among stable patients with coronary artery disease who remain at
high vascular risk (92). This trial will provide the most compre-
hensive clinical evaluation to date of the inflammatory hypothesis
in cardiac disease.
These studies highlight the emerging and pivotal role that the
NLRP3 inflammasome and IL-1β signaling play in the patho-
genesis of heart failure. Continued interrogation of the NLRP3
inflammasome in heart failure is likely to aid in identifying new
targets for therapeutic intervention, which may act synergistically
with pharmacologic chaperones to break the cycle of amyloidosis
and inflammation.
Amyloid Proteins, Heart Failure, and
Activation of “Functional Amyloid”:
Necrosome
While amyloid has primarily been described as a key mediator
of pathological processes, it has now been recognized that when
certain proteins form amyloid, it is part of their physiological role.
That is, they act as a molecular switch to promote environmental
adaptation and act as a regulator of intracellular signaling (93).
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FIGURE 4 | Cullin-RING ubiquitin ligase (CRL) activity is regulated via
neddylation and deneddylation. Cullin serves as a scaffold protein when
neddylated (conjugated with NEDD8), a reaction catalyzed by NEDD8
activating enzyme (NAE), ubiquitin conjugating enzyme (Ubc12), and a
NEDD8-specific ligase (NEDD E3). Cullin neddylation triggers displacement of
the inhibitory CAND1 (cullin-associated NEDD8-dissociated protein 1),
allowing cullin to interact with the adapter protein, Skp1, and a F-box protein
forming a functional CRL. Next, a ubiquitin charged E2 and a substrate are
brought in close proximity to foster the transfer of ubiquitin to the substrate.
After substrate ubiquitination, the COP9 Signalosome (CSN) will deneddylate
(remove NEDD8) from cullin, which triggers the disassembly of the CRL, and
frees the substrate to be degraded by the proteasome. The freed cullin can
be neddylated again to initiate another cycle, or inhibited via CAND1 binding.
Frontiers in Cardiovascular Medicine | www.frontiersin.org May 2015 | Volume 2 | Article 259
Parry et al. Targeting misfolded proteins in heart failure
This includes the receptor-interacting protein kinases RIP1 and
RIP3, which are found in the heart, and activate cell death by
forming the necrosome (93). Activation and assembly resulted
from their ability to form a fibrillar complex with amyloid proper-
ties, which was observed during in vitro and in vivo experimental
conditions (94). The RIP homotypic interaction motifs (RHIMs)
of RIP1 and RIP3mediate the assembly of heterodimeric filamen-
tous structures, which can trigger downstream signaling and cell
death (94).
In the heart, myocardial ischemia induces RIP3 expression,
which is sufficient to induce necroapoptosis (95). Conversely,
RIP3-/- mice challenged with MI had better function and less
TABLE 4 | Proteins forming amyloid as part of their functional role in cellular responses to the environment.
Proteins Species Roles Detection methods for aggregatesa
Soluble state Aggregated state
Sup35 Yeast Translation terminator Functional ThT, CR, EM, X-ray, etc
Mod5 Yeast tRNA isopentenyltransferase Functional ThT, EM
CPEB Marine snail Transcriptional activator/repressor Functional ThT, EM
Fruit fly
Pmel17 Human Melanin synthesis Functional ThT, CR, EM, X-ray
RIP1, RIP3 Human Kinases Functional ThT, CR, EM, X-ray
p62 Human Sequestosome formation Functional ThT, EM
GW182 Human P-body formation Functional EM
RCK/p54 Human P-body formation Functional EM
TIA-1 Human Stress granule formation Functional ThT, CR, EM
TDP-43 Human DNA/RNA binding protein Pathological/functional? ThT, CR, EM
FUS/TLS Human DNA/RNA binding protein Pathological/functional? EM
aThT, thioflavin T; CR, congo red; EM, electron microscopy; X-ray, X-ray diffraction.
© 2013 Elsevier Publishing. Used with permission from Furukawa and Nukina (93).
A
C
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FIGURE 5 | Targeting pathological and functional aggregates in heart
failure. Alterations drive protein unfolding and misfolding, resulting in the
formation of misfolded, toxic protein aggregates and amyloid. Such
misfolded protein structures activate pathological pro-inflammatory and
necrotic signaling complexes such as the inflammasome and necrosome.
However, protein aggregates can also activate the signalosome to assist in
clearing of mis/unfolded proteins. The continuum of protein misfolding to
protein aggregation and amyloid formation to activation of large signaling
complexes provides multiple levels for potential pharmacological therapeutic
targeting. (A) Pharmacological chaperones target misfolded and unfolded
proteins to stabilize protein conformation. Such drugs include tafamidis,
doxycycline, and tauroursodeoxycholic acid. (B) Targeting and inhibiting
large signaling structures like the inflammasome and necrosome offer new
and possibly complementary methods of treating amyloid based diseases.
To date, these targets have been inhibited through treatment with an IL-1
antagonist (inflammasome) and necrostatin-1 (necrosome). (C) Alternately,
the COP9 signalosome may offer yet another therapeutic target to reduce
the amyloidosis burden. Increasing activity of the signalosome could
function alone or in tandem with other therapies to assist in clearance of
misfolded protein aggregates and amyloid.
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hypertrophy 30 days post- infarction, accompanied by decreased
inflammatory response and decreased ROS production (95). Sim-
ilarly, inhibiting RIP1 with the small molecule necrostatin-1
(Nec-1) prevents necrotic cell death in experimental models of
cardiac ischemia (96). This model also displayed less adverse
remodeling, evidenced by less dilation, preserved systolic func-
tion, and reduced inflammation (TNFα mRNA and ROS) (96).
Taken together, these studies illustrate both the importance of
the RIP1/RIP3-mediated necrosis in ischemia, offering a new
direction for therapy to disrupt physiologic amyloid-like proteins
that contribute to pathology (97).
The COP9 Signalosome Enhances Protein
Degradation to Reduce the Misfolded
Protein Burden
Enhanced protein degradation clinically can be attempted
through blockade of the bad signaling complexes (e.g., the inflam-
masome and necrosome), or by activation of the beneficial
constitutive photomorphogenesis mutant 9 (COP9) signalosome
(CSN). Analogous to ubiquitination, proteins can be neddy-
lated via a series of enzymatic reactions to conjugate NEDD8 to
substrate proteins, such as a Cullin-RING-Ligase (CRL) (detailed
in Figure 4), triggering the assembly of a functional CRL. CRLs
are the largest family of ubiquitin ligases, including the ubiq-
uitin ligases Parkin, Mdm2, Smurf1, and XIAP, in addition to
transcription factors, such as E2F1, HIF1a, and p53 (98).
Only, recently has the role of deneddylation been explored. The
CSN is a highly conserved multiprotein complex composed of
eight subunits (CSN1–8) to form a ~350 kDa complex that dened-
dylates proteins (99) to regulate the protein degradation by ubiq-
uitin proteasome system (100). CRL deneddylation is essential to
disassemble the functional CRL and to release the ubiquitinated
substrate protein for subsequent degradation by the proteasome.
The CSN crystal structure has two organization centers: (1) a
horseshoe-shaped ring created by its six PCI domain proteins
and a large bundle formed by the carboxy-terminal α-helixes of
each subunit (101). The CSN5-CSN6 dimer is found at the core
of the helical bundle (101). Neddylated CRL binding to CSN is
sensed by CSN4, communicated to CSN5 (with CSN6), resulting
in activation of the deneddylase and regulation of downstream
ubiquitin ligases (101).
Recent studies have demonstrated the COP9 signalosome
regulates autophagosome maturation in vivo. Mice with a
cardiomyocyte-specific deletion of csn8 resulted in striking
increases in autophagic flux (evidenced by increased LC3-II/LC3I,
autophagosomes by TEM) and increased p62 protein (a functional
amyloid forming protein) (102, 103). CSN appears to regulate
Rab7, which plays a critical role in autophagosomal formation,
and may explain its regulation of autophagy (102). Furthermore,
the CSN appears to influence proteasomal activity by directly
interacting with the 26S proteasome and potentially compet-
ing with the 19S proteasome lid (104, 105). Therefore, it is
hypothesized that the overt loss of protein quality control due to
compromised autophagosome formation and removal paired with
reduced functionality of the UPS results in severe cardiomyocyte
necrosis, leading to DCM, heart failure, and death.
Inducible cardiac CSN8-/- mice demonstrated the role of CSN8
in regulating autophagic flux in vivo. The temporal cardiac Cre-
LoxP ablation of CSN8 resulted in the accumulation of neddylated
cullin (and non-cullin) proteins, increased ubiquitinated proteins,
and a significant decrease in autophagic flux (103). Autophago-
somes were markedly increased, as were oxidized proteins and
necrotic cardiomyocytes, resulting in a dilated cardiomyopathic
phenotype (103). How the COP9 signalosome is activated has not
been clearly delineated. An intriguing possibility is that, similar
to the proteasome, the COP9 signalosome can be regulated by
post-translational modifications. Currently, there are no known
proteins that post-translationally regulate the CSN; however, if
found, this approach may have great therapeutic potential with
small pharmacological modulators.
Summary: The Structural Continuum
Between Functional and Pathological
Amyloids and the Significance in Heart
Failure
The formation of amyloids has been observed as a patholog-
ical change implicated in neurodegenerative disease, including
Alzheimer’s disease, Parkinson’s disease, and polyglutamine pro-
teins (Huntington’s disease). Paralleling these pathological find-
ings and mechanisms, heart failure has similarly been found to
involve these same biological processes (31). This has led to
the multiple clinical studies underway testing pharmacological
interventions to stabilize the common TTR misfolding in cardiac
amyloidosis (Tables 1–3). However, the activation of amyloid
formation is not only a pathological state; recent evidence sug-
gests critical functional processes have similar aggregated states
(Table 4) (93). Evidence that both the necrosome and inflamma-
some can be inhibited to demonstrate the utility of targeting their
activation when aggregates have already formed, complementing
the pharmacological chaperones that largely prevent misfolded
proteins from forming and possibly reversing/removing protein
aggregation. Complementary to these three pathways, activation
of the COP9 signalosome by a yet to be determined pathway
may prove to be another way in which misfolded cardiac proteins
can be cleared to reduce future aggregate burdens. The multiple
levels in which heart failure may be targeted illustrate many
new opportunities for treating the heavy burden of heart failure
where limited therapies exist, none of which currently target the
underlying protein quality control issues outlined in this review
(Figure 5).
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